Latest revenue
$2.0M
as of 2025-12-31
Latest net income
$-265.9M
as of 2025-12-31
Net margin
-13301.2%
as of 2025-12-31
Community sentiment
Where do you think ROIV is heading?
Keep private notes on ROIV — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
ROIV vs S&P 500 · rebased to 100
Live market
delayed ≤15 min- Market cap
- $20.89B
- Enterprise value
- $19.83B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 4.62×
- Dividend yield
- 0.0%
- 52-wk high
- $32.79
- 52-wk low
- $10.71
- Beta
- —
- Shares out
- 719.3M
What this company does
ITEM 1. BUSINESS Overview Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 and TYK2 currently under review at the FDA for the treatment of dermatomyositis and also in late stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension…
AI summary unavailable — showing raw filing excerpt
Generated from ROIV's filing dated 2026-05-20
Key risks
Item 1A. RISK FACTORS Our business involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained in this Annual Report on Form 10-K, including the section entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and the related notes, as well as the risks, uncertainties and other information set forth in the reports and other materials filed or furnished by us and our majority-controlled subsidiary, Immunovant, Inc. (“Immunovant”), with the SEC. We cannot assure you that any of the events discussed in the risk factors below will…
AI summary unavailable — showing raw filing excerpt
Generated from ROIV's filing dated 2026-05-20
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.